PRTA - Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials
2024-06-07 14:15:17 ET
Summary
- Prothena Corporation is a late-stage biotech which specializes in proteinopathies and neurodegenerative diseases.
- They have a diverse pipeline. However, their main assets in attention currently are a first-in-class amyloid depleter, Birtamimab (wholly owned), and a Parkinson’s a-synuclein mAb, Prasinezumab (collab with Roche).
- Their revenue is primarily dependent on key milestone payments from collaborators.
- The stock has been dropping since its peak about a year ago, and I believe it still has room to drop for the foreseeable future due to the risk of failure of late-stage trials.
Editor's note: Seeking Alpha is proud to welcome Asker Mammadov as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more »
Editor's note: Seeking Alpha is proud to welcome Asker Mammadov as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more »